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Abstract 
Background: A history of penicillin allergy in patients is common, but only 10–15 % are truly allergic. While the gold 
standard for diagnosing penicillin allergy is challenge, it is not recommended that this be done without first carrying 
out diagnostic skin testing. This is carried out with the major determinant benzylpenicilloyl (PPL) and the minor deter-
minant mixture (MDM), consisting of penilloate, penicilloate and Penicillin G. However, since availability of the MDM is 
limited, Penicillin G alone has been used.
Methods: A retrospective chart review was carried out on patients tested for penicillin allergy in the Clinical Immu-
nology and Allergy Clinic at the Health Sciences Centre, Winnipeg, Canada between 2005 and 2013. A total of 521 
patients charts were reviewed, of whom 240 had skin testing, ImmunoCap® for IgE to Penicillin G and V and had oral 
challenges with penicillin, amoxicillin or cloxacillin.
Results: 17/240 (7.5 %) were skin test positive, 8 to PPL, 4 to MDM and 5 to Penicillin G. One was also positive on 
ImmunoCap® testing. Three patients had negative skin tests but weakly positive ImmunoCap®. 222 patients with 
negative skin tests and serological tests were challenged. Of these, 12 patients reacted to challenge. Three of the chal-
lenges were equivocal. Of the nine patients with definite positive challenges, three were tested with Penicillin G and 
six with MDM. Therefore the false negative rates for testing were 2.3 % with PPL and Penicillin G and 6.97 % for PPL 
and MDM. The difference was not significant (p = 0.0856).
Conclusions: In this group of patients with a history of penicillin allergy tested with the major determinant of benzyl 
penicillin and either MDM or Penicillin G, there was no difference in the rate of false negative testing, based on oral 
penicillin challenges. Therefore, Penicillin G can be safely used as an alternative to MDM in diagnosing penicillin 
allergy.
© 2015 Rosenfield et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Penicillin allergy is a common complaint of patients 
presenting to Allergy Clinics. Patients describe a vari-
ety of symptoms from immediate urticarial rash and 
respiratory symptoms including anaphylaxis, to more 
delayed reactions a few days after initiating the antibiotic 
or even after course completion [ [1, 2]. Previous studies 
have shown that patient histories of their reaction are not 
reliable to determine immediate or non-immediate reac-
tions to penicillin [3, 4]. When diagnosing beta-lactam 
allergy it is possible to assess both immediate and delayed 
reactions [5–8]. Diagnosis of immediate drug allergy to 
beta lactam antibiotics is made by assessing history, skin 
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testing, measurement of specific IgE levels and drug chal-
lenge [5, 9]. The gold standard for confirming IgE medi-
ated allergy is reaction within 1 h after a challenge dose is 
given [8, 10, 11].
Skin testing utilizes both skin prick testing and intra-
dermal tests [5, 9]. The major determinant Benzylpenicil-
loyl is the metabolized form of penicillin used in the form 
of benzyl penicilloyl-polylysine (PPL) for skin testing [12, 
13]. The minor determinant mixture (MDM) consists of 
penicillin and products of penicillin metabolism, specifi-
cally penilloate and penicilloate. Availability of the MDM 
as well as PPL has been variable, depending particularly 
upon location. North America particularly has had lim-
ited access to both PPL and MDM. Using both major and 
minor determinants is considered the first line method 
for diagnostic skin testing for Beta-lactam immediate 
hypersensitivity [12, 14]. However, falling rates of reac-
tivity to penicillin reagents have been reported [12, 15, 
16]. Ampicillin, amoxicillin and cephalosporins can also 
be used for skin testing when reaction to a specific drug 
is in question and skin test reactivity to semi-synthetic 
penicillin may be now be more frequent [16, 17]. The 
usefulness of testing with the complete battery of minor 
determinants has been questioned [18, 19].
We undertook a retrospective chart review of patients 
who presented to the Allergy/Clinical Immunology clinic 
with suspected penicillin allergy and compared the effi-
cacy of skin testing with PPL and MDM vs. PPL and 
penicillin alone, using open challenge as the gold stand-
ard for determining the presence or absence of penicillin 
allergy in those who were skin test negative.
Methods
Ethics
Ethics approval was obtained through the University of 
Manitoba Research Ethics Board and access to charts was 
obtained through Health Sciences Centre Department of 
Research.
Patient selection
Charts of patients who had penicillin skin testing in the 
Allergy/Immunology Clinic at Health Sciences Centre 
in Winnipeg, Manitoba were reviewed. Patients who 
were skin tested between December 2005 and 2013 were 
included. Patient selection was done by searching elec-
tronic dictation letters and billing codes for penicillin and 
penicillin challenge, and charts were reviewed.
Skin testing
All patients evaluated for penicillin allergy underwent 
skin prick testing, intradermal testing or both. Skin 
prick testing was done using a 27-gauge needle to prick 
the skin. For intradermal testing, 0.02 mL was injected. 
Reagent for the penicillin major determinant used was 
benzylpenicilloyl polylysine, in the form of Prepen 
(ALK-Abello, Canada), DAP (Diater, Spain), or labora-
tory made reagent, standardized by mass spectrometry). 
Penicillin minor antigenic determinants were a minor 
determinant mixture made in-house that included Peni-
cillin G, penilloate and penicilloate at 2  ×  102 molar 
(characterized by mass spectrometry) [20], the DAP 
MDM mixture (concentration used was identical to 
the laboratory-made reagent) or Penicillin G alone, at a 
concentration of 6.2 mg/mL. The MDM used was deter-
mined by availability. Positive control for both intra-
dermal and skin prick testing was a concentration of 
1  mg/ml Histratrol (ALK-Abello). The negative control 
for skin prick test was glycerinated phenol saline (NaCl 
0.9 %, glycerine 50 %, phenol 0.4 %) and sterile normal 
saline for intradermal testing. Ampicillin trihydrate at 
a concentration of 5  mg/mL was used if ampicillin or 
amoxicillin skin testing was required. Cloxacillin, and 
cephalosporins were used at the same concentration. 
All patients were tested with the major determinant and 
MDM or Pen G, depending on availability. Other testing 
was determined by patient history.
Skin testing was considered positive if there was a 
wheal 3  mm greater than negative control with flare at 
15 min, for either major and minor determinants.
ImmunoCap®
Blood samples from all patients were collected for Immu-
noCap® (Phadia, Sweden) testing to Penicillin G and V 
was done by the Clinical Chemistry laboratory at Health 
Sciences Centre in Winnipeg, Manitoba, Canada. A posi-
tive result is indicated by a value greater than 0.35 kU/L.
Challenge
Patients with negative skin testing and negative penicil-
lin V and G ImmunoCap® were contacted to undergo 
challenge, which was done in the Allergy/Immunology 
Clinic at Health Sciences Centre using oral penicillin V 
300 mg, amoxicillin 250 mg, Cloxacillin 250 mg, or Cla-
vulin 250/125, depending on the original clinical pre-
cipitant. If not known, penicillin or amoxicillin was used. 
Patients were observed for 1  h, and were asked to con-
tact the clinic if there was a delayed reaction, occurring 
later than 1 h. All patients met with their physician after 
the challenge. Patients with adverse events were assessed 
by the clinic physicians and outcomes, both positive and 
negative, were recorded.
Results
521 patient charts were reviewed. Seventy-six patients 
did not have complete skin tests and serology. 205 
patients did not return for challenge after negative skin 
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tests and serology. Two hundred and forty patients had all 
investigations, including skin testing, ImmunoCap® and 
challenge, or were diagnosed with penicillin allergy after 
one or more tests (skin test and ImmunoCap®). These 
240 patients were used for the analysis. Of these 240 
patients, there were 65 male and 175 female with a mean 
age of 46.7 years. Symptoms that had occurred with peni-
cillin or other beta-lactam antibiotic use are indicated 
in Table 1. Some patients had more than one symptom. 
On chart review, patients with reactions to beta-lactam 
antibiotics other than penicillin were also identified. Of 
the 240 patients, there were 17 patients who described 
reactions to amoxicillin/ampicillin, 10 to cephalosporins, 
4 to Cloxacillin, 3 to Piperacillin/tazobactam. All other 
patients reported “penicillin allergy”, whether this meant 
penicillin was the specific antibiotic causing reaction or a 
penicillin derivative is unknown.
There was 17/240 patients with positive skin tests and 
their characteristics and results can be found in Table 2. 
Sixteen of these patients had ImmunoCap® performed 
and one was positive. Three of the 17 patients under-
went challenge, because of borderline positive skin tests 
and one had a reaction during challenge. Overall, four 
patients were skin test positive to MDM and five patients 
had positive skin tests to Penicillin G. During the entire 
period of testing, eight patients were skin test positive 
to PPL, one of these was also positive to MDM and one 
reacted to Penicillin G. Two patients were skin test-posi-
tive to ampicillin.
Twelve of 222 skin test-negative patients who were 
challenged had positive reactions to challenge. Infor-
mation on these patients and their challenge reaction 
is included in Table  3, excluding the patient who had 
a positive challenge after a mildly positive skin test 
(Table  2A patient 4). Three of 12 patients who were 
positive to challenge were tested with Pen G and not 
MDM. Nine of 12 reacting to challenge had skin test-
ing with MDM. It important to note that the challenge 
of three of the patients was inconclusive, because the 
physician supervising was unsure if the reaction that 
the patients complained of was due to the oral anti-
biotic. All three patients were to return for a blinded 
challenge but they did not attend the appointment. If 
these three patients are excluded, six of nine patients 
reacting to challenge had skin testing with MDM and 
three had testing with Penicillin G. Therefore, the false 
negative rate for testing with PPL and Penicillin G was 
3/133 (2.3 %), NPV 97.74 %; CI 93.55–99.53 % and for 
testing with PPL and MDM was 6/86 (6.97  %), NPV 
93.02 %; CI 85.43–97.4 % Chi square 2.954 p = 0.0856. 
The false negative rate for testing with all reagents 
(PPL, MDM and Penicillin G) was 5.4 %, NPV 94.6 %; 
CI 90.8–96.9 %.
Discussion
The most common drug “allergy” reported in Europe 
and North America is to penicillin or its derivatives, with 
amoxicillin being the most common antibiotic prescribed 
in this class [1, 2]. However, the ability of patients to 
identify themselves as “penicillin allergic” does not corre-
late clinically with clinical IgE mediated immediate reac-
tions [3, 4].
The lack of availability of commercial reagents required 
to properly test for an IgE mediated reaction, according 
to current guidelines, has theoretically made diagnosing 
penicillin allergy a challenge in current practice [6, 9].
Important symptoms to note that suggest immedi-
ate reactions are urticaria, angioedema, gastrointestinal 
symptoms, respiratory symptoms, hypotension and ana-
phylaxis [5, 6, 8]. However, for many patients, their reac-
tion was a number of years ago and the clinical history 
is vague or unknown. Even if the patient’s history is not 
consistent with immediate hypersensitivity, skin testing 
may still be used to confirm absence of a life threaten-
ing reaction prior to challenge and is reassuring to the 
patient. However, it is important to note that negative 
skin testing results with a complete battery of penicillin 
skin test reagents does not always rule out an immediate 
allergy to penicillin [4, 21–23]. Patients should have a full 
workup including skin testing and challenge in order to 
















 Peripheral paraesthesias 2
 Change in mental status 3
 Pallor 1
 Change in temperature sensation 2
 Other 15
 Delayed 21
 Not known by patient 39
 Not mentioned in chart 17
Page 4 of 6Rosenfield et al. Allergy Asthma Clin Immunol  (2015) 11:34 
Table 2 Patients diagnosed with penicillin allergy pre-challenge
A Positive skin test, B positive specific IgE (if negative skin testing)
PPL benzyl penicilloyl-polylysine, MDM minor determinant mixture, PG Penicillin G, ND not done, AMP ampicillin, CLX Cloxacillin, CFZ ceftazidime, ANF cefazolin
A. Positive skin tests
Patient Age Sex Reaction Skin prick test Intradermal Immunocap Challenge
+ – + – PenG PenV
1 17 F Previous positive skin test, reaction 
unknown
PPL, MDM PPL MDM ND ND ND
2 44 F Rash PPL, MDM MDM PPL – – ND
3 49 M Delayed hives PPL, MDM PPL MDM – – ND
4 29 M Facial swelling PPL, MDM, AMP MDM, AMP PPL – – +
5 25 F Unknown PPL, MDM PPL MDM – – ND
6 46 M Unknown n/d n/d PPL MDM – – ND
7 78 F Delayed prolonged rash MDM PPL, CLX MDM, PPL, CLX – – ND
8 53 F Facial swelling PPL, MDM, AMP – – ND
9 71 F Oral tingling PPL, PG, AMP PPL, AMP PG – – –
10 41 F Anaphylaxis PPL PG CLX, ANF – – ND
11 72 F Delayed rash PPL (delayed) PG – + ND
12 29 M Not known PG – – ND
13 56 F Rash AMP (delayed) PPL, PG – – –
14 60 M Rash PPL, PG CFZ – – ND
15 19 F Delayed rash PG PPL, AMP – – ND
16 46 F Rash AMP PPL, PG – – ND
17 40 F Hives, throat tightness PG, AMP PPL – – ND
B. Positive specific IgE to Penicillin G or V by ImmunCap®
Patient Age Sex Reaction Skin testing negative to Immunocap
PenG PenV
1 43 F Erythema, pruritus PPL, PG – +
2 25 F Rash PPL, PG – +
3 77 F Rash, face/lip swelling PPL, PG + –
Table 3 Patients with positive challenge
Patient Age Sex Reaction SPT/ID done Challenge to Challenge reaction
1 31 F Pruritus and facial rash, hand swelling, 
dyspnea
SPT/ID-PPL, MDM, AMP PenV Pruritus, heavy chest, arm rash
2 42 F Pruritic rash, throat itch SPT/ID-PPL, MDM PenV Generalized pruritus
3 38 F Rash SPT/ID-PPL, MDM Pen V Next morning facial swelling—inconclusive
4 19 F Urticaria SPT/ID-PPL, MDM PenV Maculopapular rash forearm and hand, 
nasal and throat pruritus. Delayed -> non 
IgE mediated penicillin allergy
5 40 F Angioedema tongue SPT/ID-PPL, MDM PenV Pruritus, eye swelling
6 50 F Urticaria SPT-PPL, MDM PenV n/a
7 57 F Shortness of breath SPT-PPL, MDM PenV Pruritus, nausea—inconclusive
8 30 F Rash SPT/ID-PPL, MDM PenV Lip tingling, pruritic macular rash on chest, 
facial and back pruritus
9 47 F Unknown, previous + ID-PPL, PG PenV Throat sensation—inconclusive
10 50 F Hives ID-PPL, PG, AMP PenV Erythematous pruritus, palmar erythema
11 72 M Rash ID-PPL, PG, AMP Amox Delayed pruritic rash
12 32 F Pruritus, hives, throat closing, lip swelling, 
paraesthesia
ID-PPL, PG, AMP Amox Pruritus to back and arms
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rule out immediate hypersensitivity to penicillin as com-
pletely as possible, including, when possible, testing with 
the beta-lactam that precipitated the reaction.
The standard of practice for skin testing includes the 
use of PPL and MDM. It was previously thought that test-
ing without a complete panel of minor antigenic determi-
nants could fail to identify 10 % or more of patients with 
penicillin allergy [24–27]. When MDM are not available, 
Penicillin G has been used as an alternative, with PPL. 
Evidence for this approach comes from a study by Macy 
and Ngor [28] where they showed that 1125 patients 
would have to be skin tested with minor determinants to 
prevent one patient having a positive oral challenge with 
penicillin. This data resulted in these investigators dis-
continuing the use of penicilloate and penilloate (as com-
ponents of MDM) skin testing for diagnosis of penicillin 
allergy. They concluded that it is possible to diagnose IgE 
mediated penicillin allergy using skin testing to penicil-
loyl-polylysine and penicillin and if negative, subsequent 
oral challenge with amoxicillin. Macy reports the result 
of skin testing with PPL (Prepen, ALK-Abello, USA) 
Penicillin G and amoxicillin [18, 28]. Using this method 
there were no anaphylactic reactions for skin test nega-
tive patients undergoing challenge and only four patients 
had minor reactions (hives within 1 h) with challenge.
Another study by del Real et  al. [29] also used a skin 
testing protocol with PPL and Pen G in both the outpa-
tient and inpatient (including ICU) setting. About half 
of those patients, who were negative on testing, were 
treated with beta-lactam antibiotics and less than 2 % had 
adverse reactions. These reactions were usually rash, with 
most of them being delayed reactions. The studies by 
Macy and by Del Real show the negative predictive value 
of using only PPL and Pen G is similar to that of a full 
panel with PPL and MDM [28–30].
Even more striking were the results of Picard et  al. 
[31], who tested 563 children with a history of penicillin 
allergy only with Pen G, at a time when the PPL determi-
nant was not available commercially in North America. 
They found that 32 % were positive to skin testing with 
the Pen G preparation, and challenged the skin test nega-
tive group with the incriminated beta-lactam or amoxi-
cillin. Only 4.8  % reacted to challenge, with a NPV of 
95.2 % (95 % CI 92.5–97.1 %).
These studies give results similar to our results, where 
we found only three positive challenges out of 133 
patients challenged who were skin test negative to Peni-
cillin G and PPL. Of 86 patients who were skin test nega-
tive to PPL and MDM, there were six positive challenges. 
None of these patients had severe reactions, as seen in 
Table 3. The false negative rate for testing with PPL and 
Penicillin G was 3/130 (2.3 %), NPV 97.74 %; CI 93.55–
99.53  % and for testing with PPL and MDM was 6/86 
(6.97 %), NPV 93.02 %; CI 85.43–97.4 % Chi square 2.954 
p = 0.0856.
In contrast to Macy’s findings, a previous retrospective 
review done by Lin et al. [27] shows that by eliminating 
penicilloate and penilloate as components of the MDM 
one would fail to detect 16 % of patients with penicillin 
allergy. A minor determinant consisting of penilloate, 
penicilloate and Penicillin G will find 22.6  % of peni-
cillin allergic patients vs. 6.6  % with Penicillin G alone. 
In this study, patients with negative skin tests were not 
challenged. Therefore, it would have been expected that 
a larger number of patients would be challenge positive 
after our practice protocol shifted from using MDM to 
Penicillin G. However, it is possible that the results of 
Lin et  al. reflect a difference in the time since reaction 
between their patient population and our population. 
The longer the time since the reaction, the less likely it is 
that positive skin tests will be found [32, 33].
Overall we diagnosed 30 patients (12.55 %) with peni-
cillin allergy, either by skin tests, ImmunoCap® or chal-
lenge, which is in line with previous recent studies of 
patients with a history of penicillin allergy [17, 34]. Of the 
521 patients whose charts were reviewed, 205 patients 
were skin test and ImmunoCap® negative but were not 
challenged because they failed to return to the clinic for 
challenge.
Shortfalls of our study include the large number of 
patients who did not return for challenge. We do not 
know what the challenge results would be for the 205 
patients who were skin test and ImmunoCap® negative. 
We do not know if those patients who were challenge 
positive without skin testing to MDM would have been 
MDM skin test positive.
In future, if patents were challenged immediately after 
skin testing as in the protocol outlined by Macy, patients’ 
compliance would not be a factor. The delay in challeng-
ing was in part due to time constraints and in part due to 
the time it took for the ImmunoCap® results to become 
available.
In conclusion, we do not appear to have failed to diag-
nose penicillin allergy in patients who presented with 
suspected reactions to these antibiotics by not testing 
with the minor determinant mixture. Although we did 
have positive challenges in patients who were tested only 
with Penicillin G, this number was less than the number 
of positive challenges when testing with the complete 
MDM mixture was done, although the difference was 
not statistically significant. In addition, no challenge pro-
duced a clinically serious reaction.
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